The Goal: Find Vaccine Candidates in Neisseria meningitidis

Data derived from the Science Watch/Hot Papers database and the Web of Science (ISI, Philadelphia) show that Hot Papers are cited 50 to 100 times more often than the average paper of the same type and age. Despite the plethora of microbial genome papers, most do little more than catalog genes and analyze results, says Hervé Tettelin, a microbial genomics investigator at the Institute for Genomic Research, Rockville, Md. They normally are presented, he says, as underpinnings for further

Written byJim Kling
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Despite the plethora of microbial genome papers, most do little more than catalog genes and analyze results, says Hervé Tettelin, a microbial genomics investigator at the Institute for Genomic Research, Rockville, Md. They normally are presented, he says, as underpinnings for further inquiry. But that was not the case when Tettelin and coworkers set out to sequence a serogroup B strain of Neisseria meningitides--their goal was to find vaccine candidates. The resulting Hot Paper "is the first case of a whole genome sequence coming out with a very direct application," he says.1

Neisseria meningitidis lives peacefully in the nasopharynx until unknown factors conspire to make it cross the endothelial cell barrier, where it causes septicemia. From there, it may work its way into the meninges, with meningitis as a possible result. It is primarily a pathogen in infants, responsible for up to 5,300 cases worldwide per year, with 5% to ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies